Elanco Animal Health Incorporated (ELAN)
$
23.4
+0.46 (1.97%)
Key metrics
Financial statements
Free cash flow per share
0.5715
Market cap
11.7 Billion
Price to sales ratio
2.4727
Debt to equity
0.6136
Current ratio
2.1653
Income quality
-2.9787
Average inventory
1.7 Billion
ROE
-0.0351
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Elanco Animal Health Incorporated is an established player in the animal health sector, innovating and developing a diverse array of products designed for both pets and farm animals. The company reported an income before tax of -224,000,000.00 showcasing its pre-tax profitability. The cost of revenue for the company is $2,665,000,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $4,463,000,000.00 reflecting its overall spending. Additionally, Elanco reported selling, general, and administrative expenses of $1,430,000,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is 496,400,000.00 reflecting potential dilution effects. Elanco focuses on pet health with disease prevention products such as parasiticides and vaccines protecting pets from common parasites like worms, fleas, and ticks under renowned brands including Seresto, Advantage, Advantix, and Advocate. It also offers therapeutics for various conditions in canines and felines under the Galliprant and Claro brands. Moreover, the company provides vaccines, antibiotics, and nutritional health products for poultry and aquaculture, alongside essential products for ruminant and swine production under the Rumensin and Baytril brands. Elanco serves a broad customer base, including third-party distributors, veterinarians, and farm animal producers ranging from beef and dairy farmers to those in the pork and poultry sectors. As an organization, Elanco Animal Health operates within the Healthcare sector, driving innovation and growth within the industry. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Investors seeking budget-friendly options may find the stock affordable at $19.20 making it suitable for those who are budget-conscious. Additionally, the stock has a high average trading volume of 4,734,063.00 indicating strong liquidity in the market. With a mid-range market capitalization of $11,633,731,200.00 the company is recognized as a steady performer, showcasing its reliability and consistent contributions to the animal health field.
Is Elanco Animal Health Incorporated (ELAN) a good investment?
Investing in Elanco Animal Health Incorporated (ELAN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Elanco Animal Health Incorporated (ELAN)'s stock forecast?
Analysts predict Elanco Animal Health Incorporated stock to fluctuate between $8.02 (low) and $27.72 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Elanco Animal Health Incorporated's market capitalization?
As of 2026-03-16, Elanco Animal Health Incorporated's market cap is $11,633,731,200, based on 497,168,000 outstanding shares.
How does Elanco Animal Health Incorporated compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Elanco Animal Health Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Elanco Animal Health Incorporated (ELAN) stock?
To buy Elanco Animal Health Incorporated (ELAN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ELAN. Place an order (Market, Limit, etc.).
What is the best time to invest in Elanco Animal Health Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Elanco Animal Health Incorporated perform in the last earnings report?
Revenue: $4,715,000,000 | EPS: -$0.47 | Growth: -169.12%.
Where can I find Elanco Animal Health Incorporated's investor relations reports?
Visit https://www.elanco.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Elanco Animal Health Incorporated?
You can explore historical data from here
What is the all-time high and low for Elanco Animal Health Incorporated stock?
All-time high: $36.50 (2021-08-05) | All-time low: $7.88 (2023-05-31).
What are the key trends affecting Elanco Animal Health Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Presents at Leerink Global Healthcare Conference 2026 Transcript
seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Q4 2025 Earnings Call Transcript
zacks.com
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.14 per share a year ago.
prnewswire.com
Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day Outlook Fourth Quarter 2025 Financial Results: Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currency Reported Net Loss of $276 million, Adjusted Net Income of $64 million Adjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7% Reported EPS of $(0.56), Adjusted EPS of $0.13 Full Year 2025 Financial Results: Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025 Revenue of $4,715 million, increased 6% on a reported basis and 7% in organic constant currency Reported Net Loss of $232 million, Adjusted Net Income of $473 million Adjusted EBITDA of $901 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $(0.47), Adjusted EPS of $0.94 Net leverage ratio of 3.6x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.15 billion Revenue of $4,950 million to $5,020 million, or 4% to 6% organic constant currency growth Adjusted EBITDA of $955 million to $985 million, an increase of 8% at midpoint Adjusted EPS of $1.00 to $1.06, an increase of 10% at midpoint Year-end net leverage ratio target of 3.1x to 3.3x In line with three-year outlook introduced at December Investor Day, outlining mid-single digit top-line organic constant currency growth, high-single digit Adjusted EBITDA growth, and low double-digit Adjusted EPS growth INDIANAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2025 and provided initial guidance for both the first quarter and full year 2026. "Elanco delivered significant progress across our strategic priorities of growth, innovation, and cash in 2025," said Jeff Simmons, President and CEO of Elanco.
prnewswire.com
INDIANAPOLIS, Feb. 13, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.
seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
Elanco Animal Health earns a buy rating, driven by robust product innovation, commercial execution, and a credible deleveraging plan. ELAN's 'Big 6' innovation portfolio is set to contribute ~$1.1 billion in 2026 revenue, supporting margin expansion and portfolio renewal. Credelio Quattro and Zenrelia demonstrate ELAN's ability to capture share from incumbents, with rapid adoption and strong sequential growth.
prnewswire.com
Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age against canine atopic dermatitis and allergic dermatitis for 6 to 8 weeks of treatment, as needed USDA approval of Befrena reinforces Elanco's commitment to going beyond to deliver differentiated, high-quality products in every key therapeutic area, bolstering its leadership in canine dermatology and monoclonal antibodies (mAbs) Canine allergic and atopic dermatitis is a widespread concern amongst veterinarians, with data revealing that nearly 98% of vets say they routinely treat dogs for atopic dermatitis and that itchy dogs make up nearly 20% of their patient populationi INDIANAPOLIS, Ind., Dec. 31, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology space with the U.S. Department of Agriculture (USDA) approval of Befrena™ (tirnovetmab), a new anti-IL31 monoclonal antibody (mAb) injection targeting canine allergic and atopic dermatitis.
See all news
